Genentech's Perjeta gets boost from final CLEOPATRA data
This article was originally published in Scrip
Executive Summary
Roche/Genentech's humanized HER-2 targeting MAb Perjeta (pertuzumab) is set for a sales boost after final data from its Phase III CLEOPATRA study showed that it increased survival by 16 months when used in combination with Herceptin (trastuzumab) and docetaxel chemotherapy in previously untreated patients with HER-2 positive metastatic breast cancer.